Disease · MONDO_0007803
multiple system atrophy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. multiple system atrophy. Diseases, record MONDO_0007803. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007803
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- MSA, Multiple system atrophy (disorder), Shy-Drager syndrome, Shy-McGee-Drager syndrome, multisystem atrophy, orthostatic hypotension syndrome
- Open Targets
Drugs26
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DROXIDOPA | CHEMBL2103827 | Small molecule | Approval | DailyMed | 5 | 4 | 4 | Drugs and targets |
| IOFLUPANE I 123 | CHEMBL3989517 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| VERDIPERSTAT | CHEMBL4297594 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 4 | 4 | Drugs and targets |
| AMLENETUG | CHEMBL4594571 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AMPRELOXETINE | CHEMBL4297646 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EPIGALOCATECHIN GALLATE | CHEMBL297453 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MINOCYCLINE | CHEMBL1434 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIFAMPIN | CHEMBL374478 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RILUZOLE | CHEMBL744 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| UBIDECARENONE | CHEMBL454801 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 26
See all 26 drugsTargets35
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA2A | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 antagonist | Approval | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 antagonist | Approval | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 antagonist | Approval | https://conductscience.org/library/genes/152 | Drugs and targets |
| MAOB | Amine oxidase [flavin-containing] B | 2 | Monoamine oxidase B inhibitor | Phase 2 | https://conductscience.org/library/genes/4129 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB1 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRB3 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/155 | Drugs and targets |
1 to 10 of 35
See all 35 targetsTrials31
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03952806 | Study of BHV-3241 in Participants With Multiple System Atrophy | Phase 3 | 421 | 2023-09-29 | Multiple System Atrophy | VERDIPERSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00782340 | A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa | Phase 3 | 263 | 2014-05-16 | Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency | DROXIDOPA | Its record names the disease | ClinicalTrials.gov |
| NCT00633880 | Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) | Phase 3 | 181 | 2014-05-20 | Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency | DROXIDOPA | Its record names the disease | ClinicalTrials.gov |
| NCT00977665 | Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Phase 2 | 174 | 2015-02-26 | Multiple System Atrophy | RASAGILINE | Its record names the disease | ClinicalTrials.gov |
| NCT04095793 | Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Phase 3 | 110 | 2022-11-30 | Symptomatic Neurogenic Orthostatic Hypotension | AMPRELOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT00738062 | Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) | Phase 3 | 103 | 2014-05-16 | Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency | DROXIDOPA | Its record names the disease | ClinicalTrials.gov |
| NCT01287221 | Study of Rifampicin in Multiple System Atrophy | Phase 3 | 100 | 2014-03-28 | Multiple System Atrophy | RIFAMPIN | Its record names the disease | ClinicalTrials.gov |
| NCT02008721 | Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach | Phase 3 | 92 | 2024-03-12 | Multiple System Atrophy | EPIGALOCATECHIN GALLATE | Its record names the disease | ClinicalTrials.gov |
| NCT05104476 | A Study of Lu AF82422 in Participants With Multiple System Atrophy | Phase 2 | 64 | 2024-12-27 | Multiple System Atrophy | AMLENETUG | Its record names the disease | ClinicalTrials.gov |
| NCT02388295 | AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients | Phase 2 | 59 | 2017-09-25 | Multiple System Atrophy, MSA | VERDIPERSTAT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsComparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rasagiline Mesylate vs Placebo: serious adverse events | 29 of 84 | 23 of 90 | 174 | NCT00977665 | Trial comparisons |
| Rifampicin vs Placebo: serious adverse events | 3 of 50 | 12 of 50 | 100 | NCT01287221 | Trial comparisons |
| EGCG as Putative Neuroprotective Agent vs Placebo: Effect of Treatment (Epigallocatechin Gallate vs Placebo) on Safety and Tolerability: Discontinuation Rates Because of Hepatotoxicity | 2 of 47 | 0 of 45 | 92 | NCT02008721 | Trial comparisons |
| EGCG as Putative Neuroprotective Agent vs Placebo: Clinical Safety and Tolerability of EGCG Measured by Death Rates | 4 of 47 | 2 of 45 | 92 | NCT02008721 | Trial comparisons |
| EGCG as Putative Neuroprotective Agent vs Placebo: deaths from any cause | 4 of 47 | 2 of 45 | 92 | NCT02008721 | Trial comparisons |
| EGCG as Putative Neuroprotective Agent vs Placebo: serious adverse events | 18 of 47 | 8 of 45 | 92 | NCT02008721 | Trial comparisons |
| Lu AF82422 vs Placebo: deaths from any cause | 2 of 40 | 2 of 21 | 61 | NCT05104476 | Trial comparisons |
| Lu AF82422 vs Placebo: serious adverse events | 12 of 40 | 7 of 21 | 61 | NCT05104476 | Trial comparisons |
| Exenatide vs Standard of Care: Loss of Independent Ambulation | 2 of 25 | 2 of 25 | 50 | NCT04431713 | Trial comparisons |
| Exenatide vs Standard of Care: deaths from any cause | 2 of 25 | 2 of 25 | 50 | NCT04431713 | Trial comparisons |
1 to 10 of 18
See all 18 comparisons in its trialsPapers from its trials17
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007803
GET https://conductscience.org/api/diseases/v1/MONDO_0007803/drugs?page=2